Bridge Diagnostics LLC
Bridge Diagnostics LLC was paid $8.52M by Medicaid between Aug 2020 and Sep 2024, across 30 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 64% of everything it billed.
ALISO VIEJO, CA 92656
Next to other Clinical Medical Laboratory providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 32,470 | $728K | |
| 2021 | 99,967 | $2.25M | |
| 2022 | 181,410 | $5.40M | |
| 2023 | 3,486 | $154K | |
| 2024incomplete | 178 | $0.00 |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 64% | 117,806 | 69,620 | $5.46M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 12% | 70,314 | 44,913 | $1.02M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11% | 76,944 | 42,080 | $960K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.8% | 7,102 | 5,056 | $496K |
| 87481 | 1.7% | 6,771 | 4,886 | $149K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 1,428 | 1,332 | $136K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,065 | 5,591 | $63K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,567 | 5,955 | $62K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,030 | 5,570 | $62K |
| 87511 | <1% | 6,097 | 4,640 | $34K | |
| 87653 | <1% | 2,653 | 1,904 | $26K | |
| 87640 | <1% | 2,492 | 1,871 | $23K |
18 more codes
| 87529 | <1% | 990 | $7K | |
| 87634 | <1% | 179 | $6K | |
| 87563 | <1% | 1,110 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 42 | $5K |
| 87186 | <1% | 486 | $3K | |
| 87500 | <1% | 664 | $3K | |
| 87641 | <1% | 593 | $2K | |
| 81328 | 0% | 16 | $0.00 | |
| 81232 | 0% | 16 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 16 | $0.00 |
| 81241 | 0% | 16 | $0.00 | |
| 81355 | 0% | 16 | $0.00 | |
| 81226 | 0% | 18 | $0.00 | |
| 81227 | 0% | 16 | $0.00 | |
| 81230 | 0% | 16 | $0.00 | |
| 81231 | 0% | 16 | $0.00 | |
| 81240 | 0% | 16 | $0.00 | |
| 81225 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.